These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 21317148

  • 1. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction.
    Solomon SD, Shin SH, Shah A, Skali H, Desai A, Kober L, Maggioni AP, Rouleau JL, Kelly RY, Hester A, McMurray JJ, Pfeffer MA, Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) Investigators.
    Eur Heart J; 2011 May; 32(10):1227-34. PubMed ID: 21317148
    [Abstract] [Full Text] [Related]

  • 2. Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren.
    Shah AM, Shin SH, Takeuchi M, Skali H, Desai AS, Køber L, Maggioni AP, Rouleau JL, Kelly RY, Hester A, Keefe D, McMurray JJ, Pfeffer MA, Solomon SD.
    Eur J Heart Fail; 2012 Feb; 14(2):185-92. PubMed ID: 21965526
    [Abstract] [Full Text] [Related]

  • 3. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [Abstract] [Full Text] [Related]

  • 4. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M, Petrescu L, Riviş AI, Suşan RM, Burghină D, Dan R, Cozma D, Drăgulescu SI.
    Rom J Intern Med; 2005 May; 43(3-4):187-98. PubMed ID: 16812979
    [Abstract] [Full Text] [Related]

  • 5. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.
    Krum H, Massie B, Abraham WT, Dickstein K, Kober L, McMurray JJ, Desai A, Gimpelewicz C, Kandra A, Reimund B, Rattunde H, Armbrecht J, ATMOSPHERE Investigators.
    Eur J Heart Fail; 2011 Jan; 13(1):107-14. PubMed ID: 21169387
    [Abstract] [Full Text] [Related]

  • 6. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
    Dietz R, Dechend R, Yu CM, Bheda M, Ford J, Prescott MF, Keefe DL.
    J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
    [Abstract] [Full Text] [Related]

  • 7. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study.
    Pitt B, Latini R, Maggioni AP, Solomon SD, Smith BA, Wright M, Prescott MF, McMurray JJ.
    Eur J Heart Fail; 2011 Jul; 13(7):755-64. PubMed ID: 21467028
    [Abstract] [Full Text] [Related]

  • 8. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K.
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [Abstract] [Full Text] [Related]

  • 9. Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in Syrian cardiomyopathic hamsters.
    Crespo MJ, Cangiano JL, Altieri PI, Escobales N.
    J Cardiovasc Pharmacol; 2012 Jun; 59(6):547-52. PubMed ID: 22370958
    [Abstract] [Full Text] [Related]

  • 10. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K.
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [Abstract] [Full Text] [Related]

  • 11. Combination angiotensin converting enzyme and direct renin inhibition in heart failure following experimental myocardial infarction.
    Connelly KA, Advani A, Advani S, Zhang Y, Thai K, Thomas S, Krum H, Kelly DJ, Gilbert RE.
    Cardiovasc Ther; 2013 Apr; 31(2):84-91. PubMed ID: 21884026
    [Abstract] [Full Text] [Related]

  • 12. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
    McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J, Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators.
    Circ Heart Fail; 2008 May; 1(1):17-24. PubMed ID: 19808266
    [Abstract] [Full Text] [Related]

  • 13. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G, Nicolosi GL, Chiariello M, Ferrari R, Remme P, Tavazzi L.
    Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [Abstract] [Full Text] [Related]

  • 14. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study.
    Ferrari R, Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators.
    Arch Intern Med; 2006 Mar 27; 166(6):659-66. PubMed ID: 16567606
    [Abstract] [Full Text] [Related]

  • 15. Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.
    Higashikuni Y, Takaoka M, Iwata H, Tanaka K, Hirata Y, Nagai R, Sata M.
    Hypertens Res; 2012 Jan 27; 35(1):62-9. PubMed ID: 21833001
    [Abstract] [Full Text] [Related]

  • 16. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.
    Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP, ASTRONAUT Investigators and Coordinators.
    JAMA; 2013 Mar 20; 309(11):1125-35. PubMed ID: 23478743
    [Abstract] [Full Text] [Related]

  • 17. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A.
    Am J Hypertens; 2007 Jan 20; 20(1):11-20. PubMed ID: 17198906
    [Abstract] [Full Text] [Related]

  • 18. Aliskiren: an oral renin inhibitor for the treatment of hypertension.
    Lam S, Choy M.
    Cardiol Rev; 2007 Jan 20; 15(6):316-23. PubMed ID: 18090068
    [Abstract] [Full Text] [Related]

  • 19. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction).
    Schroten NF, Damman K, Hemmelder MH, Voors AA, Navis G, Gaillard CA, van Veldhuisen DJ, Van Gilst WH, Hillege HL.
    Am Heart J; 2015 May 20; 169(5):693-701.e3. PubMed ID: 25965717
    [Abstract] [Full Text] [Related]

  • 20. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA.
    Circulation; 2005 Jun 28; 111(25):3411-9. PubMed ID: 15967846
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.